{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:41:36Z","timestamp":1790757696094,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Bortezomib is a pivotal drug for the management of multiple myeloma. However, bortezomib is a neurotoxic anticancer drug responsible for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is associated with psychological distress and a decrease of health-related quality of life (HRQoL), but little is known regarding bortezomib-related CIPN. This single center, cross-sectional study assessed the prevalence and severity of sensory\/motor CIPN, neuropathic pain and ongoing pain medications, anxiety, depression, and HRQoL, in multiple myeloma patients after the end of bortezomib treatment. Paper questionnaires were sent to patients to record the scores of sensory and motor CIPNs (QLQ-CIPN20), neuropathic pain (visual analogue scale and DN4 interview), anxiety and depression (HADS), the scores of HRQoL (QLQ-C30 and QLQ-MY20) and ongoing pain medications. Oncological data were recorded using chemotherapy prescription software and patient medical records. The prevalence of sensory CIPN was 26.9% (95% CI 16.7; 39.1) among the 67 patients analyzed and for a mean time of 2.9 \u00b1 2.8 years since the last bortezomib administration. The proportion of sensory CIPN was higher among patients treated by intravenous and subcutaneous routes than intravenous or subcutaneous routes (<jats:italic>p<\/jats:italic> = 0.003). QLQ-CIPN20 motor scores were higher for patients with a sensory CIPN than those without (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) and were correlated with the duration of treatment and the cumulative dose of bortezomib (coefficient: 0.31 and 0.24, <jats:italic>p<\/jats:italic> = 0.01 and 0.0475, respectively), but not sensory scores. Neuropathic pain was screened in 44.4% of patients with sensory CIPN and 66.7% of them had ongoing pain medications, but none were treated with duloxetine (recommended drug). Multivariable analysis revealed that thalidomide treatment (odds-ratio: 6.7, 95% CI 1.3; 35.5, <jats:italic>p<\/jats:italic> = 0.03) and both routes of bortezomib administration (odds-ratio: 13.4, 95% CI 1.3; 139.1, <jats:italic>p<\/jats:italic> = 0.03) were associated with sensory CIPN. Sensory and motor CIPNs were associated with anxiety, depression, and deterioration of HRQoL. Sensory CIPN was identified in a quarter of patients after bortezomib treatment and associated with psychological distress that was far from being treated optimally. There is a need to improve the management of patients with CIPN, which may include better training of oncologists regarding its diagnosis and pharmacological treatment.<\/jats:p>","DOI":"10.3389\/fphar.2021.637593","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T16:31:55Z","timestamp":1619109115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":55,"title":["Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Marie","family":"Selvy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Kerckhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fantine","family":"Barreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Busserolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Giraudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Cabrespine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Chaleteix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Soubrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lemal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Balayssac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"B2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdt409","article-title":"Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin","volume":"25","author":"Alberti","year":"2014","journal-title":"Ann. Oncol."},{"key":"B3","volume-title":"Practical statistics for medical research","author":"Altman","year":"1999"},{"key":"B4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3988\/jcn.2019.15.4.511","article-title":"Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived neurotropic factor protein levels and A gene polymorphism","volume":"15","author":"Azoulay","year":"2019","journal-title":"J. Clin. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00277-017-2927-8","article-title":"The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry","volume":"96","author":"Beijers","year":"2017","journal-title":"Ann. Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00520-015-3032-y","article-title":"Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice","volume":"24","author":"Beijers","year":"2016","journal-title":"Support Care Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s0895-4356(00)00314-0","article-title":"Adjusting for multiple testing-when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1093\/annonc\/mdx520","article-title":"The past and future of 'reported outcomes' in studies on chemotherapy neuropathy","volume":"28","author":"Beutler","year":"2017","journal-title":"Ann. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/pon.5176","article-title":"Anxiety and depression mediate the association between chemotherapy\u2010induced peripheral neuropathy and fatigue: results from the population\u2010based PROFILES registry","volume":"28","author":"Bonhof","year":"2019","journal-title":"Psycho\u2010Oncology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pain.2004.12.010","article-title":"Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)","volume":"114","author":"Bouhassira","year":"2005","journal-title":"Pain"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","article-title":"Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study","volume":"27","author":"Chibaudel","year":"2009","journal-title":"Jco"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"B13","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/cancers11122037","article-title":"Pain management in patients with multiple myeloma: an update","volume":"11","author":"Coluzzi","year":"2019","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","article-title":"Chemotherapy-induced peripheral neuropathy: where are we now?","volume":"160","author":"Colvin","year":"2019","journal-title":"Pain"},{"key":"B16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.leukres.2009.07.022","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients","volume":"34","author":"Corso","year":"2010","journal-title":"Leuk. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3747\/co.23.2780","article-title":"Impact of oxaliplatin-induced neuropathy in patients with colorectal cancer: a prospective evaluation at a single institution","volume":"23","author":"Dault","year":"2016","journal-title":"Curr. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1158\/0008-5472.CAN-14-2060","article-title":"A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy","volume":"74","author":"de Carvalho Barbosa","year":"2014","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France","volume":"19","author":"Despi\u00e9gel","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"Elm","year":"2007","journal-title":"J. Clin. Epidemiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2288-2-8","article-title":"Do multiple outcome measures require p-value adjustment?","volume":"2","author":"Feise","year":"2002","journal-title":"BMC Med. Res. Methodol."},{"key":"B22","unstructured":"Avis d\u2019experts relatif \u00e0 l\u2019\u00e9volution du discours public en mati\u00e8re de consommation d\u2019alcool en France\n            FranceSant\u00e9. Publique.\n          2017"},{"key":"B23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1533-2500.2012.00554.x","article-title":"Chemotherapy-induced neuropathic pain and its relation to cluster symptoms in breast cancer patients treated with paclitaxel","volume":"13","author":"Golan-Vered","year":"2013","journal-title":"Off. J. World Inst. Pain"},{"key":"B24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","article-title":"Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties","volume":"15","author":"Griffith","year":"2010","journal-title":"J. Peripher. Nerv. Syst. JPNS"},{"key":"B25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/jnen\/nlx043","article-title":"Bortezomib-induced muscle toxicity in multiple myeloma","volume":"76","author":"Guglielmi","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"Jco"},{"key":"B28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/jjco\/hyaa056","article-title":"Effects of the publication of clinical guidelines for the management of chemotherapy-induced peripheral neuropathy on the administration preferences of oncology specialists: Japanese association of supportive care in cancer","volume":"50","author":"Hirayama","year":"2020","journal-title":"Jpn. J. Clin. Oncol. Hyaa056"},{"key":"B29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.clml.2017.06.035","article-title":"Evaluation of bortezomib-induced neuropathy using total neuropathy score (reduced and clinical versions) and NCI CTCAE v4.0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction","volume":"17","author":"Lakshman","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1188\/17.ONF.580-588","article-title":"The content validity of a chemotherapy-induced peripheral neuropathy patient-reported outcome measure","volume":"44","author":"Lavoie Smith","year":"2017","journal-title":"Onf"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1007\/s00520-017-3780-y","article-title":"Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel\/carboplatin-induced peripheral neuropathy in NCCTG\/Alliance clinical trials","volume":"25","author":"Le-Rademacher","year":"2017","journal-title":"Support Care Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/hon.2706","article-title":"Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials","volume":"38","author":"Li","year":"2020","journal-title":"Hematological Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"Jco"},{"key":"B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s41687-020-0180-8","article-title":"The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment","volume":"4","author":"Mendoza","year":"2020","journal-title":"J. Patient Rep. Outcomes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0123866","DOI":"10.1371\/journal.pone.0123866","article-title":"Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy","volume":"10","author":"Minarik","year":"2015","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1312","article-title":"Risk factors for chemotherapy\u2010induced peripheral neuropathy in patients receiving taxane\u2010 and platinum\u2010based chemotherapy","volume":"9","author":"Molassiotis","year":"","journal-title":"Brain Behav."},{"key":"B39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12885-019-5302-4","article-title":"Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy","volume":"19","author":"Molassiotis","year":"","journal-title":"BMC Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.clinthera.2012.02.007","article-title":"A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in medicaid","volume":"34","author":"Oladapo","year":"2012","journal-title":"Clin. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s00520-015-2648-2","article-title":"Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib","volume":"23","author":"Peng","year":"2015","journal-title":"Support Care Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1023\/a:1008344507482","article-title":"Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy","volume":"9","author":"Postma","year":"1998","journal-title":"Ann. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"Jco"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"Jco"},{"key":"B47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"CD010816","DOI":"10.1002\/14651858.CD010816.pub2","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14740338.2020.1764934","article-title":"The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials","volume":"19","author":"Selvy","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/jcm9082400","article-title":"Long-term prevalence of sensory chemotherapy-induced peripheral neuropathy for 5 Years after adjuvant folfox chemotherapy to treat colorectal cancer: a multicenter cross-sectional study","volume":"9","author":"Selvy","year":"","journal-title":"Jcm"},{"key":"B50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00520-020-05928-6","article-title":"Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists\u2019 professional practices","volume":"12","author":"Selvy","year":"2021","journal-title":"Support Care Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1136\/bmjspcare-2018-001755","article-title":"Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry","volume":"10","author":"Servadio","year":"2019","journal-title":"BMJ Support. Palliat. Carepalliat. Care"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s11136-017-1635-0","article-title":"The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice","volume":"26","author":"Simon","year":"2017","journal-title":"Qual. Life Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/NCC.0000000000000596","article-title":"Psychometric testing of the European organisation for research and treatment of cancer quality of life questionnaire-chemotherapy-induced peripheral neuropathy 20-item scale using pooled chemotherapy-induced peripheral neuropathy outcome measures standardization and alliance for clinical trials in oncology A151408 study data","volume":"42","author":"Smith","year":"2019","journal-title":"Cancer Nurs."},{"key":"B55","doi-asserted-by":"publisher","first-page":"204062071983902","DOI":"10.1177\/2040620719839025","article-title":"Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis","volume":"10","author":"Song","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/0284186X.2018.1556804","article-title":"Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy","volume":"58","author":"Soveri","year":"2019","journal-title":"Acta Oncologica"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/aas.12697","article-title":"Prevalence and determinants of medication non-adherence in chronic pain patients: a systematic review","volume":"60","author":"Timmerman","year":"2016","journal-title":"Acta Anaesthesiol. Scand."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12338","article-title":"Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Velasco","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"B60","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/OTT.S97457","article-title":"Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients","volume":"587","author":"Xia","year":"2016","journal-title":"Ott"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom burden, perceived control, and quality of life among patients living with multiple myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B62","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.637593\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T16:32:13Z","timestamp":1619109133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.637593\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":62,"alternative-id":["10.3389\/fphar.2021.637593"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.637593","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"article-number":"637593"}}